Apyx Medical (APYX) Cash & Equivalents (2010 - 2026)

Apyx Medical's Cash & Equivalents history runs 17 years deep, the most recent figure standing at $31.1 million for Q1 2026.

• Quarterly Cash & Equivalents changed 0.41% year-over-year to $31.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $31.1 million (changed 0.41% YoY) and the FY2025 annual result came in at $31.7 million, changed 0.0% from the prior year.
• Cash & Equivalents was $31.1 million for Q1 2026 at Apyx Medical, down from $31.7 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $43.7 million in Q4 2023 and bottomed at $10.2 million in Q4 2022.
• A 5-year average of $26.5 million and a median of $28.0 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents tumbled 66.98% — and 2023, when it soared 328.3%.
• Apyx Medical's Cash & Equivalents stood at $10.2 million in 2022, then surged by 328.3% to $43.7 million in 2023, then dropped by 27.29% to $31.7 million in 2024, then dropped by 0.0% to $31.7 million in 2025, then dropped by 1.9% to $31.1 million in 2026.
• Business Quant data shows APYX's Cash & Equivalents at $31.1 million in Q1 2026, $31.7 million in Q4 2025, and $25.1 million in Q3 2025.